Catalyst Wire Dossier Catalyst Wire Dossier

Diabetes-specific oral nutritional supplement (low-carbohydrate, high-monounsaturated fatty acids)

· Fresenius Kabi
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Diabetes-specific oral nutritional supplement (low-carbohydrate, high-monounsaturated fatty acids), covering 2012-07-02 to 2012-07-02. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients [NA]

See pricing